These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33345829)

  • 1. Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain.
    Pantouli F; Grim TW; Schmid CL; Acevedo-Canabal A; Kennedy NM; Cameron MD; Bannister TD; Bohn LM
    Neuropharmacology; 2021 Mar; 185():108439. PubMed ID: 33345829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal.
    Grim TW; Schmid CL; Stahl EL; Pantouli F; Ho JH; Acevedo-Canabal A; Kennedy NM; Cameron MD; Bannister TD; Bohn LM
    Neuropsychopharmacology; 2020 Jan; 45(2):416-425. PubMed ID: 31443104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
    Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
    Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents.
    Kopruszinski CM; Swiokla J; Lee YS; Navratilova E; VanderVeen L; Yang M; Liu Y; Miyazaki T; Schmidt WK; Zalevsky J; Porreca F
    Cell Mol Neurobiol; 2021 Jul; 41(5):949-960. PubMed ID: 32107752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.
    Lei W; Vekariya RH; Ananthan S; Streicher JM
    J Pain; 2020; 21(1-2):146-160. PubMed ID: 31201990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats.
    Lemberg KK; Kontinen VK; Siiskonen AO; Viljakka KM; Yli-Kauhaluoma JT; Korpi ER; Kalso EA
    Anesthesiology; 2006 Oct; 105(4):801-12. PubMed ID: 17006080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administration.
    Stevenson GW; Giuvelis D; Cormier J; Cone K; Atherton P; Krivitsky R; Warner E; St Laurent B; Dutra J; Bidlack JM; Szabò L; Polt R; Bilsky EJ
    Psychopharmacology (Berl); 2020 Apr; 237(4):1195-1208. PubMed ID: 31912192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G protein-gated inwardly rectifying potassium (KIR3) channels play a primary role in the antinociceptive effect of oxycodone, but not morphine, at supraspinal sites.
    Nakamura A; Fujita M; Ono H; Hongo Y; Kanbara T; Ogawa K; Morioka Y; Nishiyori A; Shibasaki M; Mori T; Suzuki T; Sakaguchi G; Kato A; Hasegawa M
    Br J Pharmacol; 2014 Jan; 171(1):253-64. PubMed ID: 24117458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in nociception and morphine antinociception in mice fed a high-fat diet.
    Nealon CM; Patel C; Worley BL; Henderson-Redmond AN; Morgan DJ; Czyzyk TA
    Brain Res Bull; 2018 Apr; 138():64-72. PubMed ID: 28684345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat.
    Lemberg K; Kontinen VK; Viljakka K; Kylänlahti I; Yli-Kauhaluoma J; Kalso E
    Anesth Analg; 2006 Jun; 102(6):1768-74. PubMed ID: 16717324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice.
    Yang PP; Yeh GC; Yeh TK; Xi J; Loh HH; Law PY; Tao PL
    Pharmacol Res; 2016 Sep; 111():867-876. PubMed ID: 27496654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats.
    Austin Zamarripa C; Edwards SR; Qureshi HN; Yi JN; Blough BE; Freeman KB
    Drug Alcohol Depend; 2018 Nov; 192():158-162. PubMed ID: 30261403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.
    Largent-Milnes TM; Guo W; Wang HY; Burns LH; Vanderah TW
    J Pain; 2008 Aug; 9(8):700-13. PubMed ID: 18468954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible involvement of prolonging spinal µ-opioid receptor desensitization in the development of antihyperalgesic tolerance to µ-opioids under a neuropathic pain-like state.
    Narita M; Imai S; Nakamura A; Ozeki A; Asato M; Rahmadi M; Sudo Y; Hojo M; Uezono Y; Devi LA; Kuzumaki N; Suzuki T
    Addict Biol; 2013 Jul; 18(4):614-22. PubMed ID: 21812868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [(35)S]GTPγS binding and opioid tolerance and efficacy in mouse spinal cord.
    Madia PA; Navani DM; Yoburn BC
    Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
    Tham SM; Angus JA; Tudor EM; Wright CE
    Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biasing G
    Sanchez GA; Smrcka AV; Jutkiewicz EM
    Mol Pharmacol; 2024 Jun; 106(1):47-55. PubMed ID: 38769020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment.
    Withey SL; Spealman RD; Bergman J; Paronis CA
    J Pharmacol Exp Ther; 2019 Nov; 371(2):544-554. PubMed ID: 31413139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
    Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML
    Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.